Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19 TORONTO, Canada -- April 18, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, Canada -- April 12, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Expected to seek DSMB approval to proceed with EUA application to the FDA in...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to...
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film...
Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19 Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment...
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer Novel discovery and research originated from Universidad Central del...
Revive Confirms No Material Undisclosed Information Toronto, Ontario, Canada -- August 12, 2021 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd...
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution...
Revive Therapeutics Approved to Trade on the OTCQB Market TORONTO, June 25, 2021 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF, FRANKFURT:...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.01 | 0.01 | 0.005 | 297976 | 0.01 | CS |
| 4 | 0 | 0 | 0.01 | 0.01 | 0.005 | 334098 | 0.00842445 | CS |
| 12 | 0 | 0 | 0.01 | 0.02 | 0.005 | 409523 | 0.0119481 | CS |
| 26 | -0.025 | -71.4285714286 | 0.035 | 0.035 | 0.005 | 403712 | 0.01342685 | CS |
| 52 | -0.02 | -66.6666666667 | 0.03 | 0.04 | 0.005 | 296679 | 0.01901764 | CS |
| 156 | -0.465 | -97.8947368421 | 0.475 | 0.6 | 0.005 | 350778 | 0.17154059 | CS |
| 260 | -0.05 | -83.3333333333 | 0.06 | 0.92 | 0.005 | 871750 | 0.31361174 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
